A clinical-stage biotech developing drugs that protect the gut microbiome from antibiotic damage, plus cancer therapies, with no products on the market yet.
No revenue; annual net losses of USD -0.03B in 2024 and 2025, funded by investors, not sales.
No approved products or revenue, so competitors like Pfizer or Merck could easily replicate any eventual drug; the science is promising but unproven.
Key events, in time order
On-chain data shows Hayes bought 6.16M SYN; price surged past $0.65
None yet
None yet
Arthur Hayes has divested from $SYN, reallocating capital into $ENA. This transaction suggests a shift in investment focus from SYN to ENA.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
